Pannysylvania Magazine

DelveInsight’s “Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Epidermal growth factor receptor-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Epidermal growth factor receptor-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Epidermal growth factor receptor-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR-Non Small Cell Lung Cancer Market Forecast

Some of the key facts of the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report:

• The EGFR inhibitor market size was valued at approximately USD 7.0 billion in 2025 and is projected to reach USD 16.0 billion by 2036, registering a CAGR of 7.9% during the 2026–2036 forecast period, driven by the growing adoption of targeted therapies and continued advancements in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

• In May 2026, Hoth Therapeutics, Inc. has received clinical trial authorization in Spain to expand its Phase IIa study evaluating HT-001, a topical therapy developed to manage skin toxicities associated with epidermal growth factor receptor (EGFR) inhibitors. The authorization follows encouraging interim results from the ongoing U.S. study, where HT-001 demonstrated promising efficacy in reducing the severity of EGFR inhibitor-induced acneiform skin rashes. By extending the trial internationally, Hoth aims to accelerate the clinical development of HT-001 and address a significant unmet need by helping cancer patients better manage treatment-related skin toxicities, potentially improving adherence to EGFR-targeted cancer therapies.

• In February 2026, Bicara Therapeutics Inc. has reported preliminary safety and efficacy findings from an exploratory Phase Ib expansion cohort investigating ficerafusp alfa at a 2,000 mg every-two-weeks (Q2W) dosing schedule in combination with pembrolizumab as a first-line treatment for patients with HPV-negative recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data, evaluating a higher-dose, less-frequent dosing regimen, were featured in a plenary presentation at the 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS).

• In January 2026, The US FDA has accepted Summit’s Biologics License Application (BLA) for review based on data from the Phase III HARMONi trial and has set a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026.

• In January 2026, Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for review. The application seeks approval of ivonescimab in combination with chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received tyrosine kinase inhibitor (TKI) therapy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026.

• In December 2025, Amivantamab-vmjw is a pioneering, fully human bispecific antibody designed to simultaneously target the epidermal growth factor receptor (EGFR) and the mesenchymal–epithelial transition factor (MET). It marks a major breakthrough for patients with EGFR-driven non–small cell lung cancer (NSCLC), especially those with EGFR exon 20 insertion mutations a group long known for poor prognosis and limited response to standard EGFR tyrosine kinase inhibitors (TKIs). Since receiving accelerated FDA approval in 2021, amivantamab has broadened its clinical relevance, backed by strong evidence from pivotal studies such as CHRYSALIS, PAPILLON, and MARIPOSA.

• In June 2025, The FDA has granted accelerated approval to Dato-DXd for treating adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR mutations and has progressed following prior EGFR-targeted therapies and platinum-based chemotherapy. This approval represents a major advancement for patients with limited treatment options after disease progression. The decision is supported by pooled efficacy data from two clinical trials: the Phase 2, single-arm TROPION-Lung05 study and the global, open-label Phase 3 TROPION-Lung01 trial.

• In March 2025, Johnson & Johnson (NYSE: JNJ) announced overall survival (OS) results from the Phase 3 MARIPOSA study, a key benchmark in cancer treatment. In a direct comparison with osimertinib, the combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) showed a significant improvement in OS for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions (ex19del) or L858R mutations. The median OS is expected to surpass three years—the median observed with osimertinib—and has not yet been reached. This marks the first and only study to demonstrate a statistically significant and clinically meaningful OS benefit over osimertinib.

• In January 2025, BlossomHill Therapeutics, Inc., a privately-held clinical-stage biotechnology company specializing in small molecule therapies for cancer and autoimmune diseases, has announced the dosing of the first patient cohort in the SOLARA study (NCT06706076). SOLARA is a global, open-label, Phase 1/2 dose escalation and expansion trial evaluating the safety, efficacy, and tolerability of BH-30643 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR or HER2 mutations.

• In January 2025, AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US and granted Priority Review. The application seeks approval for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including an EGFR-targeted treatment.

• In 2025, the United States held the largest market share for EGFR inhibitors among the 7MM, accounting for approximately 60% of the total market.

• Germany shows consistent growth in NSCLC revenues, reflecting steady adoption of EGFR-targeted therapies and increasing treatment penetration. HNC revenues accelerate significantly after the late 2020s, suggesting entry of new targeted or biologic therapies that drive market expansion. Meanwhile, CRC revenues grow modestly, highlighting a stable but limited-growth market due to the presence of established treatment options.

• Cetuximab continues to dominate the EGFR inhibitor market in Head and Neck Cancer, primarily because it remains the only widely approved EGFR-targeted therapy for this indication. As a result, it is extensively utilized in clinical practice both as a monotherapy and in combination with chemotherapy or platinum-based regimens, making it the cornerstone of EGFR-directed treatment strategies for patients with head and neck cancer.

• In 2036, among all the therapies for EGFR NSCLC, the highest revenue is estimated to be generated by amivantamab (RYBREVANT) ± lazertinib (LAZCLUZE) followed by osimertinib (TAGRISSO), in the US.

• According to DelveInsight’s estimates, the total number of incident cases of NSCLC in the 7MM was nearly 115,000 cases in 2025 and is projected to increase during the forecasted period.

• The total number of incident cases of NSCLC in the United States was nearly 30,000 in 2025.

• In the 7MM, the US accounted for the highest incident cases of EGFR mutated cancers in 2025, with around 118,790 cases; these numbers are expected to increase during the forecast period.

• In 2025, the EGFR-expressing incident cases of selected indications in Japan included 55,000 cases of NSCLC, 33,000 cases of CRC, and 17,000 cases of HNC.

• In the EU4 and the UK, Germany accounted for the highest incident cases of EGFR mutated cancers with approximately 35,000 cases reported in 2025.

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Companies: AstraZeneca, J&J Innovative Medicine, Hansoh Pharmaceutical, Cullinan Oncology/Taiho Pharmaceutical, Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies: TAGRISSO, RYBREVANT, Aumolertinib, Zipalertinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others

• The Epidermal growth factor receptor-NSCLC epidemiology based on gender analyzed that in the United States, 7 out of 10 patients had metastatic NSCLC (Stage III b and IV)

• The Epidermal growth factor receptor-Non Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermal growth factor receptor-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the Epidermal growth factor receptor-Non Small Cell Lung Cancer market dynamics.

Epidermal growth factor receptor-Non Small Cell Lung Cancer Overview

EGFR-Non Small Cell Lung Cancer (EGFR-NSCLC) is a subtype of non-small cell lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. These mutations lead to abnormal cell growth and division. EGFR-NSCLC is more common in non-smokers, women, and people of East Asian descent.

Get a Free sample for the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report –

https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology Segmentation:

The Epidermal growth factor receptor-Non Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of EGFR Inhibitor

• Total Incident cases of EGFR by Indication

Download the report to understand which factors are driving Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology trends @ EGFR-Non Small Cell Lung Cancer Epidemiology Forecast

Epidermal growth factor receptor-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermal growth factor receptor-Non Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Epidermal growth factor receptor-Non Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epidermal growth factor receptor-Non Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies and Key Companies

• Osimertinib (TAGRISSO): AstraZeneca

• Sunvozertinib (ZEGFROVY): Dizal Pharmaceutical

• Erbitux: Eli Lilly and Company/ Bristol Meyer Squibb/Merck KGaA

• Zipalertinib: Cullinan Oncology/Taiho Pharmaceutical

• Firmonertinib: ArriVent BioPharma

• Ivonescimab (SMT112): Akeso Biopharma/Summit Therapeutics

• TAGRISSO: AstraZeneca

• RYBREVANT: J&J Innovative Medicine

• Aumolertinib: Hansoh Pharmaceutical

• Zipalertinib: Cullinan Oncology/Taiho Pharmaceutical

• Telisotuzumab Vedotin(Teliso-V): Abbvie

• Lazertinib (Leclaza): Yuhan Corporation/ Janssen Research & Development)

• Nazartinib (EGF816): Novartis

• Patritumab deruxtecan (HER3-DXd): Daiichi Sankyo

Discover more about therapies set to grab major Epidermal growth factor receptor-Non Small Cell Lung Cancer market share @ EGFR-Non Small Cell Lung Cancer Treatment Market

Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Drivers

• Increasing Use of Biomarker Testing

• Increase in the Mutation Specific Trials Activity and Approval

• Increasing Incidence of NSCLC

• Rich Pipeline and label expansion of approved therapies

Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Barriers

• Cost-Effectiveness of Therapies

• Small Patient Populations for Specific Subsets of NSCLC

• Generic or Biosimilar Erosion

Scope of the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Companies: AstraZeneca, J&J Innovative Medicine, Hansoh Pharmaceutical, Cullinan Oncology/Taiho Pharmaceutical, Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies: TAGRISSO, RYBREVANT, Aumolertinib, Zipalertinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others

• Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapeutic Assessment: Epidermal growth factor receptor-Non Small Cell Lung Cancer current marketed and Epidermal growth factor receptor-Non Small Cell Lung Cancer emerging therapies

• Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Dynamics: Epidermal growth factor receptor-Non Small Cell Lung Cancer market drivers and Epidermal growth factor receptor-Non Small Cell Lung Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Epidermal growth factor receptor-Non Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Access and Reimbursement

To know more about Epidermal growth factor receptor-Non Small Cell Lung Cancer companies working in the treatment market, visit @ EGFR-NSCLC Clinical Trials and Therapeutic Assessment

Table of Contents

1. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for Epidermal growth factor receptor-Non Small Cell Lung Cancer

3. SWOT analysis of Epidermal growth factor receptor-Non Small Cell Lung Cancer

4. Epidermal growth factor receptor-Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Overview at a Glance

6. Epidermal growth factor receptor-Non Small Cell Lung Cancer Disease Background and Overview

7. Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Epidermal growth factor receptor-Non Small Cell Lung Cancer

9. Epidermal growth factor receptor-Non Small Cell Lung Cancer Current Treatment and Medical Practices

10. Epidermal growth factor receptor-Non Small Cell Lung Cancer Unmet Needs

11. Epidermal growth factor receptor-Non Small Cell Lung Cancer Emerging Therapies

12. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Outlook

13. Country-Wise Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Analysis (2022–2036)

14. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Drivers

16. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Barriers

17. Epidermal growth factor receptor-Non Small Cell Lung Cancer Appendix

18. Epidermal growth factor receptor-Non Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/